Why Vertex Pharmaceuticals Incorporated (VRTX) is the Best Pharma Stock to Buy According to Hedge Funds
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a ...
Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio?
Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Zacks Investment Research on MSN1d
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
In the latest market close, Vertex Pharmaceuticals (VRTX) reached $502.92, with a +1.51% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of ...
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's second consecutive day of gains.
Vertex Pharmaceuticals (NASDAQ:VRTX) Rating Increased to Buy at StockNews.com
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Zacks.com on MSN2d
Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know
Vertex Pharmaceuticals (VRTX) reachead $495.29 at the closing of the latest trading day, reflecting a +1.42% change compared to its last close.
Vertex’s non-opioid pain drug gets some UnitedHealth coverage
The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
Nasdaq4d
Where Will Vertex Pharmaceuticals Be in 10 Years?
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...